Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Peritoneal mesothelial cells as a target of local aldosterone action: upregulation of connective tissue growth factor expression via serum- and glucocorticoid-inducible protein kinase 1.
Okazaki A, Mori Y, Nakata M, Kimura T, Sonomura K, Sakoda C, Matsuoka E, Ishida M, Yamahara H, Kishimoto N, Nakagawa H, Matsubara H. Okazaki A, et al. Among authors: nakagawa h. Kidney Blood Press Res. 2009;32(3):151-60. doi: 10.1159/000221063. Epub 2009 May 26. Kidney Blood Press Res. 2009. PMID: 19468237
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Wiviott SD, et al. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415602 Clinical Trial.
Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib.
Terashima T, Kido H, Takata N, Hayashi T, Seki A, Nakagawa H, Nio K, Toyama T, Iida N, Yamada S, Shimakami T, Takatori H, Arai K, Yamashita T, Mizukoshi E, Yamashita T. Terashima T, et al. Among authors: nakagawa h. Cancers (Basel). 2025 Jan 16;17(2):278. doi: 10.3390/cancers17020278. Cancers (Basel). 2025. PMID: 39858059
Retrospective evaluation of a novel ultrasound-based imaging analysis software for predicting radiofrequency ablation areas.
Sato M, Tateishi R, Zohar Y, Sato J, Watadani T, Moriyama M, Wake T, Nakagomi R, Kinoshita MN, Nakatsuka T, Minami T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Yamada R, Even N, Amitai I, Abu Y, Fujishiro M, Koike K. Sato M, et al. Among authors: nakagawa h. PLoS One. 2025 Jan 17;20(1):e0317469. doi: 10.1371/journal.pone.0317469. eCollection 2025. PLoS One. 2025. PMID: 39823502 Free PMC article.
Metachronous Pancreatic Cancer with Pancreaticobiliary Maljunction Diagnosed Five Years after Cholecystectomy for Gallbladder Cancer, in Which Follow-up Imaging was Possible Until the Onset of Cancer: A Case Report and Review of the Literature.
Miyazawa M, Yanagi M, Chiba T, Nagai K, Kido H, Sugimoto S, Nishitani M, Orita N, Takata N, Hayashi T, Seki A, Nakagawa H, Nio K, Terashima T, Iida N, Yamada S, Takatori H, Shimakami T, Mizukoshi E, Honda M, Yamashita T. Miyazawa M, et al. Among authors: nakagawa h. Intern Med. 2025 Jan 15. doi: 10.2169/internalmedicine.4581-24. Online ahead of print. Intern Med. 2025. PMID: 39814388 Free article.
Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma.
Terashima T, Nio K, Koshikawa N, Ueno M, Toyama T, Miyazawa M, Hayashi T, Seki A, Nakagawa H, Iida N, Yamada S, Takatori H, Shimakami T, Yoshimura T, Yoshida E, Nakagawa M, Seiki M, Yamashita T. Terashima T, et al. Among authors: nakagawa h. BJC Rep. 2025 Jan 14;3(1):2. doi: 10.1038/s44276-024-00116-z. BJC Rep. 2025. PMID: 39809945 Free PMC article.
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798579 Clinical Trial.
4,319 results